We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




High-Sensitivity Version of Common Blood Test May Predict Early Onset of Hypertension

By LabMedica International staff writers
Posted on 02 Sep 2015
Print article
A study analyzing blood samples from over 5,000 people suggests that a more sensitive version of the standard blood test for cardiac troponin T (CT-T)—long used to verify heart muscle damage from heart attacks—could help identify people on the verge of developing hypertension well before it can be detected with a blood pressure machine.

High blood pressure’s stealthy onset, its variability over time, and the need to re-check over multiple visits before making a diagnosis, have hampered efforts to treat and prevent this disease. Results of the new study using a high-sensitivity CT-T test, led by Johns Hopkins University (Baltimore, MD, USA) investigators, showed that people with subtle elevations in CT-T — below levels detectable with the standard test — were more likely to be diagnosed with hypertension within a few years. The test could also identify those at risk for left ventricular hypertrophy, the abnormal thickening of the lower left chamber of the heart, a common consequence of untreated high blood pressure. Therefore, subtle increase in CT-T levels may have value as a marker predicting high blood pressure and subclinical heart damage.

“Identifying those at risk for hypertension as well as those in the earliest stages of the disease would allow us to intervene much sooner, either with lifestyle changes or medication, before the condition develops fully and has had a chance to damage organs,” said first author Bill McEvoy, MBBCh, MHS, assistant professor at the Johns Hopkins University School of Medicine.

The standard CT-T test is relatively inexpensive (USD 10–20) and is the gold-standard test for cardiac muscle damage from recent or ongoing heart attacks, indicating whether someone with chest pain or other cardiac symptoms is having a heart attack. However results are often “normal” for many with other forms of cardiac damage unrelated to heart attacks. The new version is calibrated to detect far lower CT-T levels, even trace amounts released by heart cells injured by spikes in blood pressure that come and go unnoticed, often for years. It is currently used across Europe, but not yet available for clinical use in the USA.

“Our data suggest that the high-sensitivity CT-T test could flag people with normal blood pressure in the doctor’s office who are at high risk for hypertension and other poor outcomes,” said senior study investigator Elizabeth Selvin, PhD, MPH, professor at Johns Hopkins Bloomberg School of Public Health. For example, people whose blood pressures yo-yo during the day or those whose pressures don’t decrease as normal during sleep, can be missed during regular blood pressure checks. Such people are prone to developing silent heart damage from erratic blood pressure and often progress to hypertension within a few years. “That group may benefit from more aggressive monitoring, including a 24-hour blood pressure monitor,” said Prof. Selvin.

If further clinical trials affirm the reliability of the high-sensitivity CT-T test as a screening tool for subclinical or future hypertension, it could also help clinicians ward off other devastating complications, including kidney brain and eye damage.

The summary of the findings, by McEvoy JW et al., were published online ahead of print July 7, 2015, in the journal Circulation.

Related Links:

Johns Hopkins University


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: A false color scanning election micrograph of lung cancer cells grown in culture (Photo courtesy of Anne Weston)

AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell

Current strategies for matching cancer patients with specific treatments often depend on bulk sequencing of tumor DNA and RNA, which provides an average profile from all cells within a tumor sample.... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more

Pathology

view channel
Image: Fingertip blood sample collection on the Babson Handwarmer (Photo courtesy of Babson Diagnostics)

Unique Hand-Warming Technology Supports High-Quality Fingertip Blood Sample Collection

Warming the hand is an effective way to facilitate blood collection from a fingertip, yet off-the-shelf solutions often do not fulfill laboratory requirements. Now, a unique hand-warming technology has... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.